360
Participants
Start Date
May 20, 2024
Primary Completion Date
February 28, 2027
Study Completion Date
April 30, 2027
LY4170156
Intravenous
Bevacizumab
IV
carboplatin
IV
RECRUITING
Icon Cancer Centre South Brisbane, QLD
RECRUITING
Cancer Research SA, Adelaide, SA
RECRUITING
New York University (NYU) Clinical Cancer Center, New York
RECRUITING
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RECRUITING
National Cancer Center, Goyang-si Gyeonggi-do
RECRUITING
NYU Langone Health - Long Island, Mineola
RECRUITING
Istituto Clinico Humanitas, Rozzano
RECRUITING
Istituto Europeo di Oncologia, Milan
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Oncopole Claudius Regaud, Toulouse
RECRUITING
The Ohio State University (OSU) Wexner Medical Center, Columbus
RECRUITING
Institut de Cancerologie de l'Ouest - site St-Herblain, Saint-Herblain
RECRUITING
Hospital Clinico Universitario de Valencia, Valencia
RECRUITING
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
RECRUITING
Centre Leon Berard, Lyon
RECRUITING
START Mountain Region, West Valley City
RECRUITING
HonorHealth, Scottsdale
RECRUITING
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
NOT_YET_RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
The University of Texas - MD Anderson Cancer Center, Houston
RECRUITING
Shizuoka Cancer Center, Shizuoka
RECRUITING
National Cancer Center Hospital, Tokyo
RECRUITING
Cancer Institute Hospital of JFCR, Tokyo
RECRUITING
Hospital Universitario Vall d'Hebron, Barcelona
Eli Lilly and Company
INDUSTRY